QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) Partner to Provide Most Advanced AI Platform for Brain Diseases


QYNAPSE SAS, a French medical technology company, today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off of the universities of McGill and Laval. The goal of this strategic collaboration is to combine technologies, patents and expertise of TPMD with the know-how and product line of Qynapse – and thus form the most advanced artificial intelligence (AI) platform. in the field of imaging brain diseases such as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis.Over the past fifteen years, the founders of TPMD, Prof. Louis Collins (mcgill university, Montreal, Canada) and Prof. Simon duchesne (University Laval, Quebec, Canada) have established one of the most impressive scientific and technological asset bases in brain imaging and applied AI to this field, supported by more than 500 scientific publications and communications. These technologies are already used in Canada by leading research consortia and private international actors in studies specifically related to neurodegeneration, such as Alzheimer’s disease.

QYNAPSE is already marketing its first QyScore® medical device in clinical centers L’Europe  and United States. Its platform is also used in clinical trials involving dozens of centers around the world. Collaboration with TPMD will allow QYNAPSE to extend the applications of its QyScore® software for other brain diseases such as stroke, epilepsy, autism, schizophrenia and head trauma – and also to develop new software to predict the clinical progression of individual patients and optimize recruitment into clinical trials.

The acquisition of TPMD by QYNAPSE covers 15 patents, including 9 issued in United States and Canada, grouped into nine families of technological assets. The founders of TPMD will join the scientific board of QYNAPSE, paving the way for a long-term collaboration.

According to Prof. Louis Collins: « QYNAPSE is a very promising partner for TPMD and both McGill and Laval universities, which will allow us to accelerate the regulatory approval and commercialization of the technologies we have developed in recent years“. Professor Duchesne adds, “Indeed, with QYNAPSE we will have access to a partner already well established in the medical field. We look forward to providing clinicians with the tools they need to improve diagnostic accuracy, aid prognosis, and guide the treatment of conditions such as dementia and cerebrovascular disease..  »

« We are delighted to partner with two of the world’s leading experts in brain imaging and to expand our scientific and clinical collaborations with two major centers of excellence in this field. ” said Olivier Courrèges, CEO of QYNAPSE. ” This collaboration will create a unique technological framework, strengthening our ability to deploy powerful tools to address two major challenges: the performance of clinical trials and the personalized management of brain diseases, which affect more than one in six people worldwide. »

Once finalized, TPMD will be integrated into QYNAPSE CANADA Inc. and TPMD’s scientific and commercial partnership contracts will be managed by this new entity.


Founded in 2015, QYNAPSE is a French medical technology company, a spin-off of the CATI consortium of neuroimaging research laboratories. The company develops and markets solutions using the potential of quantitative imaging and artificial intelligence to optimize the diagnosis, prognosis and follow-up of patients with neurological diseases.
QYNAPSE is headquartered at Paris, France) et en Boston (United States).


Founded in 2011, TRUE POSITIVE MEDICAL DEVICE Inc. is a spin-off of the work of Prof. Simon duchesne at CERVO Brain Research Center and at the University Laval and Prof. Louis Collins at the Montreal Neurological Institute and mcgill university. The company designs, validates and operates a brain image processing platform to aid in the diagnosis and prognosis of neurological and psychiatric diseases.
TPMD is based on Montréal and Quebec city (QC, Canada).

Logo – https://mma.prnewswire.com/media/1311169/Qynapse_Logo.jpg
Photo – https://mma.prnewswire.com/media/1311170/QyScore_application.jpg

Media contact
Ysé Sallé de Chou
ysalledecho[email protected]



Please enter your comment!
Please enter your name here